PATENT CLAIM ANALYSIS

Application Number: 15868272
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "006400"]

Abstract:
The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.

Claim (Index 34):
A pharmaceutical composition comprising:\n a. an insulin; b. citrate, in a concentration from about 5 to about 25 mM; c. treprostinil, in a concentration from about 0.04 to about 20 \u03bcg/mL; d. a preservative; and e. zinc, in a concentration sufficient to provide at least 2 zinc ions per six molecules of insulin; and having a pH of about 7.0 to about 7.8 at room temperature, wherein the pharmaceutical composition provides for an uptake of insulin into the blood, as measured by early \u00bd Tmax, that is at least 20% more rapid than for compositions which contain the same insulin but which do not contain citrate or treprostinil.

Metadata:
- Claim Count in Document: 77.0
- Percentile: 86.0
- Lexical Diversity: 1.29412
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15241412', '14963279', '14781342', '15259101', '13507262']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7050101810768629
- 35 USC 102 Novelty (BERT): 0.5548556369157132
- Combined Prediction Score: 0.6899947266607479
- Mean Citation Score: 340.59009
- Max Citation Score: 409.67368
- Similarity Product: 333.0894473061085

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test